Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KX-826 in Healthy Males with Androgenetic Alopecia
NCT04502901Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in androgenetic alopecia (AGA) comparing Experimental Group - KX-826 with Control Group - Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events at 19 days and Incidence of study drug related TEAEs at 19 days. Started Jan 2020; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04502901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502901.